CETRORELIX Drug Patent Profile
✉ Email this page to a colleague
When do Cetrorelix patents expire, and what generic alternatives are available?
Cetrorelix is a drug marketed by Gland, Humanwell, Livzon Grp, Qilu, Teva Pharms Inc, and Xiromed. and is included in six NDAs.
The generic ingredient in CETRORELIX is cetrorelix acetate. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the cetrorelix acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cetrorelix
A generic version of CETRORELIX was approved as cetrorelix acetate by TEVA PHARMS INC on August 12th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CETRORELIX?
- What are the global sales for CETRORELIX?
- What is Average Wholesale Price for CETRORELIX?
Summary for CETRORELIX
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Drug Prices: | Drug price information for CETRORELIX |
| DailyMed Link: | CETRORELIX at DailyMed |
Recent Clinical Trials for CETRORELIX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Trust Fertility Clinic | PHASE4 |
| Martin Blomberg Jensen | PHASE2 |
| Dunamenti REK Pannon Clinic | PHASE4 |
Anatomical Therapeutic Chemical (ATC) Classes for CETRORELIX
US Patents and Regulatory Information for CETRORELIX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gland | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 218150-001 | Apr 25, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Qilu | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 217776-001 | Apr 16, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Humanwell | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 218740-001 | Apr 29, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Livzon Grp | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 214540-001 | Apr 24, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Xiromed | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 218061-001 | Jun 3, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Teva Pharms Inc | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 215737-001 | Aug 12, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
